Stock VIR VIR BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
11.23 USD -6.30% Intraday chart for Vir Biotechnology, Inc. +9.35% +11.63%
Jun. 06 Morgan Stanley Adjusts Price Target on Vir Biotechnology to $15 From $12, Maintains Equal-Weight Rating MT
Jun. 05 Sector Update: Health Care Stocks Steady Premarket Wednesday MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vir Biotechnology - Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus
AQ
Morgan Stanley Adjusts Price Target on Vir Biotechnology to $15 From $12, Maintains Equal-Weight Rating
MT
Sector Update: Health Care Stocks Steady Premarket Wednesday
MT
Sector Update: Health Care
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Focus Shifts to Market Reports This Week
MT
Vir Biotechnology Says Mid-Stage Trial for Tobevibart, Elebsiran Show Clinically Significant Efficacy
MT
Transcript : Vir Biotechnology, Inc. - Special Call
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
BU
Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran
CI
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
BU
Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024
CI
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
BU
Multiple Abstracts highlighting Vir Biotechnology's Latest Hepatitis Delta and B Data Accepted for Presentation at the EASL Congress 2024
AQ
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
BU
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
BU
Transcript : Vir Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM
Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M
MT
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIR Stock
  4. News Vir Biotechnology, Inc.